Biogen (NASDAQ:BIIB) Stock Unloaded Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $15,001 and $50,000 in Biogen stock on June 2nd. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Voyager Technologies (NYSE:VOYG) on 6/15/2026.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 6/4/2026.
• Purchased $15,001 – $50,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/3/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/2/2026.
• Purchased $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.

Biogen Stock Performance

Shares of NASDAQ:BIIB opened at $200.36 on Thursday. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The company has a 50-day moving average price of $197.84 and a 200-day moving average price of $187.82. The company has a market cap of $29.58 billion, a price-to-earnings ratio of 21.50 and a beta of 0.16. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $219.72.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts anticipate that Biogen Inc. will post 13.95 EPS for the current year.

Institutional Investors Weigh In On Biogen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Rothschild Investment LLC increased its stake in shares of Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares in the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after buying an additional 57 shares in the last quarter. Kera Capital Partners Inc. increased its stake in Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock worth $316,000 after buying an additional 58 shares in the last quarter. Parallel Advisors LLC raised its holdings in Biogen by 1.5% during the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after acquiring an additional 65 shares during the period. Finally, Itau Unibanco Holding S.A. raised its holdings in Biogen by 24.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 66 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on BIIB. Oppenheimer lifted their price objective on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Thursday, May 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Morgan Stanley lowered their price target on Biogen from $224.00 to $222.00 and set an “equal weight” rating for the company in a research report on Wednesday. Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Finally, Argus upgraded shares of Biogen to a “hold” rating in a research note on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average price target of $218.15.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.